What peptides is Jennifer Aniston using? The short answer
Jennifer Aniston has said more about peptides than almost any other celebrity, and still not enough to answer the question in this headline. In the WSJ. Magazine Fall Women's Style issue of August 2023, when she was 54, she said she gets weekly peptide injections for her skin and added the line every beauty desk has recycled since: "I do think that's the future." Two other habits fall under the same word: an oral collagen peptide powder from Vital Proteins, where she is a paid brand partner with the title of chief creative officer, and topical skincare built around peptides.
What she did not do, then or since, is name the compound in the syringe. Not the molecule, not the clinic, not the reason for a weekly cadence. Anyone telling you which peptide Jennifer Aniston injects is guessing, and we are not going to guess. What we can do is take each route, oral, topical and injected, and explain what peptide means there, what has been measured in people, and where the regulatory record stands in September 2026.
That matters because the three routes are three product categories sharing a word and little else: a food, a set of cosmetic ingredients, and an unapproved or compounded drug with the thinnest evidence of the three. Reading them as one regimen, as most coverage does, is the first mistake to avoid.
Layer one: what a collagen peptide actually is
Start with the powder, because it has the best data and the least mystery. Collagen peptides, also sold as hydrolysed collagen, are gelatin from bovine hide, fish skin or pig sources cut enzymatically into short fragments: not one molecule but thousands of chains averaging a few thousand daltons, dominated by glycine, proline and hydroxyproline in the repeating pattern that makes collagen collagen.
Digestion cuts those chains further, and the interesting part is what survives. Japanese work from the mid-2000s showed that after a person drinks a gelatin hydrolysate, dipeptides such as prolyl-hydroxyproline appear intact in the blood for several hours, and in fibroblast culture those dipeptides nudge proliferation and hyaluronic acid synthesis. That is the whole mechanistic argument: a food-derived fragment reaches the circulation and weakly signals the cells that build dermal matrix. Plausible and modest, and neither adjective should be dropped.
The disclosure belongs here, not in a footnote. Vital Proteins pays Aniston to be its public face and she holds an executive title there. That does not make her wrong about liking the product, but it makes her endorsement a marketing asset rather than a testimonial, and a reader should weight it that way.
What the collagen trials measured, and why they are not injection evidence
Oral collagen is unusual among celebrity peptides in having randomised, placebo-controlled trials. The pattern is consistent: a few dozen to a little over a hundred women, usually aged 35 to 65, take a few grams of hydrolysate or a matching placebo daily for eight to twelve weeks, and skin is measured with instruments, corneometry for hydration, cutometry for elasticity, silicone replicas for wrinkle depth. A 2014 German trial of a bovine hydrolysate reported a significant gain in elasticity at eight weeks; a companion trial reported reduced eye-wrinkle volume and a rise in dermal procollagen. Both were funded by the ingredient's manufacturer.
Meta-analyses have pooled the field. A 2021 systematic review of nineteen randomised trials, roughly eleven hundred participants, found improved hydration and elasticity at about ninety days; a 2023 meta-analysis of twenty-six trials, around seventeen hundred participants, pointed the same way with the same caveats: real on the instruments, small in absolute terms, short in follow-up, heterogeneous across products, and overwhelmingly generated by companies that sell the powder. None of it shows that a person looks younger to another person, because that was rarely the endpoint.
None of it involves approval, either. In the United States collagen peptides are dietary supplements under the 1994 supplement law, free to make structure and function claims without FDA review of efficacy, and no authorised European Union health claim links collagen hydrolysate to skin. The best-evidenced product Aniston has named probably does a little, measurably, for a while, and nobody has been required to prove more.
It is also a different category from anything in a syringe. A collagen peptide is a random fragment of an animal structural protein, eaten, digested and absorbed in tiny amounts; an injected research peptide is a single defined sequence placed under the skin to hit a specific receptor, bypassing digestion entirely. One is nutrition with a signalling footnote, the other is pharmacology, and borrowing the powder's trial data to support the shot is misdirection.
Layer two: the peptides in the serum
Topical cosmetic peptides fall into three families. Signal peptides mimic fragments of matrix proteins and prompt fibroblasts to make more. Neurotransmitter-inhibiting peptides interfere with the machinery that releases acetylcholine at the neuromuscular junction, aiming softly at what botulinum toxin does hard. Carrier peptides shuttle a metal, which in practice means the copper peptide GHK-Cu in cream form.
Three ingredients dominate the label copy. Acetyl hexapeptide-8, marketed as Argireline, mimics the amino-terminal end of SNAP-25 and competes for a place in the SNARE complex that vesicles need to release acetylcholine; botulinum toxin cleaves SNAP-25 outright, which is why the effect sizes are not in the same league. Palmitoyl pentapeptide-4, marketed as Matrixyl, is a five-residue fragment of type I procollagen with a fatty acid attached, shown in 1993 to stimulate collagen synthesis in cultured fibroblasts. Palmitoyl tripeptide-1 is the GHK sequence of the copper peptide with a palmitate tail in place of the copper ion, usually paired with palmitoyl tetrapeptide-7 as Matrixyl 3000.
All three are lawful cosmetic ingredients in the United States, the European Union and the United Kingdom, which means no regulator has assessed whether they work. A cosmetic may claim to improve the appearance of skin; the moment it claims to rebuild collagen or treat wrinkles it has made a drug claim and become an unapproved new drug.
What split-face and vehicle-controlled studies actually show
The best single study in the category is a twelve-week, double-blind, split-face trial of palmitoyl pentapeptide-4 published in 2005. Ninety-three women applied the peptide moisturiser to one side of the face and the identical vehicle to the other, and the peptide side improved more on fine lines and wrinkles by image analysis and expert grading. Split-face is the strongest design cosmetics has, since each participant is her own control. The study was run by a consumer products company that sells the ingredient.
Argireline's founding 2002 study was tiny: ten women, a five percent emulsion around the eyes for thirty days, wrinkle depth on silicone replicas down by up to about thirty percent. A 2013 randomised, placebo-controlled study in sixty Chinese subjects reported measured wrinkle roughness falling by roughly half over four weeks against essentially no change with placebo. Palmitoyl tripeptide-1 leans mostly on supplier data in trade literature. Independent reviews of the category from 2009 onward reach one verdict: measurable, small, industry-funded and short.
Then there is the barrier. The 500-dalton rule holds that molecules much larger than 500 daltons rarely cross intact stratum corneum in useful amounts. Argireline is roughly 890 daltons, palmitoyl pentapeptide-4 roughly 800, palmitoyl tripeptide-1 roughly 580. The palmitate tails exist to make the molecules lipophilic enough to partition into the barrier, and that engineering is the industry's own admission that delivery is the hard part. How much reaches a living fibroblast from a finished product has never been quantified in a way a consumer can check.
Layer three: what an LA clinic means by a weekly skin peptide shot
Now the syringe. Aniston did not name it, so what follows decodes the phrase, not the person. Spend time around the longevity and aesthetic clinics of Beverly Hills and West Hollywood and you learn that a weekly peptide injection for skin almost always means one of two things. The first is GHK-Cu, the copper tripeptide, drawn up as a subcutaneous shot on the theory that a molecule which signals fibroblasts in a dish will signal them from the bloodstream. The second is a growth hormone secretagogue, most often sermorelin or CJC-1295 paired with ipamorelin, sold for skin on the argument that more growth hormone means more IGF-1 and more IGF-1 means more collagen.
Weekly is a tell, though an imperfect one. The long-acting, albumin-bound form of CJC-1295 was engineered to hold IGF-1 elevated for about a week after a single injection, so a weekly schedule fits it; GHK-Cu clinics are looser about cadence, and sermorelin and ipamorelin are short-acting molecules the market usually gives far more often. None of that lets anyone infer what one actress receives, and we would caution against reading a calendar as a diagnosis. What the two candidates do share is a route the evidence never travelled: neither has a controlled trial with skin as the endpoint after injection.
Injected GHK-Cu: no trial, and a copper question
Topical GHK-Cu has controlled human data in photoaged facial skin and in diabetic foot ulcers. Injected GHK-Cu has none: no registered or published controlled human study for skin, hair, tendon or anything else. What supports the practice is cell-culture work in which the concentration was chosen by the experimenter and delivered straight to the cells, plus the observation that plasma GHK declines with age, a marker of falling matrix turnover rather than a proven cause of anything.
Injection also changes the copper arithmetic. About a sixth of the complex by mass is copper, and the body regulates copper mainly at intestinal absorption, a step a needle skips. In 2026 this moved from theoretical objection to reported problem. The Hollywood Reporter quoted physicians warning of copper toxicity with overdose and of immune reactions, described grey-market vials found to contain arsenic and lead, and recorded the nickname for the flushing and skin reaction some users develop, the copper uglies. NPR's September 2026 report said the trend had moved from creams to injections ahead of the science.
There is no approved injectable GHK-Cu anywhere. The FDA placed it in the category of bulk substances raising significant safety concerns in September 2023, which bars pharmacies from compounding it, and the vials that circulate are labelled research use only, meaning the seller makes no representation that the contents are sterile, correctly identified or fit for a human being.
Sermorelin, CJC-1295, ipamorelin: the growth hormone route to skin
The secretagogue pitch for skin has a real physiological root. Growth hormone drives the liver to make IGF-1, IGF-1 stimulates fibroblasts, and the famous 1990 study of twelve men over sixty given growth hormone for six months reported skin thickness up by roughly seven percent. Three and a half decades of anti-ageing marketing rest on that number, measured in a dozen men without blinding, follow-up or any assessment of how the skin looked.
What followed was less flattering. A 2007 systematic review of controlled growth hormone trials in healthy older adults found modest body-composition changes, no gain in strength or function, and more oedema, joint pain, carpal tunnel syndrome and impaired fasting glucose. A two-year randomised trial of the oral secretagogue MK-677 restored young-adult IGF-1 and added lean mass without improving anything a person could feel, while raising fasting glucose. A secretagogue is a smaller, feedback-limited version of an intervention that already failed the ageing test at full strength, and no trial of sermorelin, CJC-1295 or ipamorelin has ever used skin as an endpoint.
The three are not interchangeable. Sermorelin is the first 29 residues of GHRH, once approved in the United States as a diagnostic and paediatric growth agent, discontinued in 2008 for commercial reasons, and now reachable only through patient-specific compounding on a prescription. CJC-1295 is a stabilised GHRH fragment in two forms sharing one name, short-acting and albumin-bound, whose human data stops at phase 1 pharmacokinetics. Ipamorelin is a selective ghrelin-receptor agonist that raises growth hormone with little effect on cortisol or prolactin, and its development ended in a discontinued phase 2 programme for an unrelated indication.
One more thing. Higher circulating IGF-1, even within the normal range, tracks with modestly higher cancer risk in pooled prospective cohorts. That is an association, not proof that raising IGF-1 by injection causes harm, and no trial in this class has been large or long enough to answer it.
The regulatory record as of September 2026
No peptide of any kind is approved by the FDA, the EMA or the MHRA as an injectable treatment for skin ageing. The only growth hormone secretagogue with a current FDA approval is tesamorelin, cleared in 2010 to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy and for nothing else. Using it for skin would be off-label use of a drug never tested for that purpose.
In September 2023 the FDA placed CJC-1295, ipamorelin and GHK-Cu, with sixteen other substances, in Category 2 of its 503A bulk-substances evaluation, the category for compounds that raise significant safety risks, barring pharmacies from compounding them. The politics shifted in 2026: the Health Secretary promised in February to restore access, the agency moved twelve peptides out of Category 2 in April into an undefined holding position, and a July advisory committee voted narrowly to allow compounding of several, BPC-157 and TB-500 among them. GHK-Cu, CJC-1295 and ipamorelin were not among the seven voted on. A second meeting on five more is due before the end of February 2027, and even a favourable vote requires rulemaking that realistically runs into 2027. None of the three has a lawful compounding pathway today, let alone an approval.
It is worth noticing who declined to join the trend. The board-certified dermatologists quoted in the 2026 coverage of Aniston's remarks said, in varying words, that they do not inject anything that is not FDA-approved. That is the position the evidence supports, and it marks a striking gap between the specialty that treats skin for a living and the clinics selling weekly peptide shots for it.
Once the famous name comes off the vial
Strip Aniston's name from the story and what remains is unremarkable. A food supplement with small, short, industry-funded trials showing a little more hydration and elasticity on a probe. Cosmetic ingredients with split-face and vehicle-controlled data that reach significance in a few dozen faces and land far below what a retinoid or an in-office procedure delivers. And an injectable category whose two likeliest candidates have, between them, no controlled human trial with skin as an endpoint, one compounding ban, one discontinued approval and one phase 1 pharmacokinetic study.
That is not an argument that she is wrong. She is 57 now and said at 54 that she thinks injections are the future, and peptide drugs are the future of a good deal of medicine, as the GLP-1 story has made unmissable. But a future is a forecast and a weekly shot is a present-tense decision, and once the celebrity is removed from that decision its evidence is far thinner than the coverage implies. Of her three peptides, the one in the coffee is the best supported, the one in the serum the best understood, and the one in the syringe the one nobody has tested.